Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study)
Abstract To compare the efficacy of methotrexate and apremilast in psoriatic arthritis (PsA). This Single blinded (physician), parallel group, randomized controlled trial was conducted at a single centre between October 2019 and December 2020. Adult PsA patients (age > 18 years), fulfilling CASPAR criteria, not on methotrexate/apremilast in last 3 months and never receiving bDMARDs or, JAK inhibitors, having active articular disease (one or more swollen joint or, having one or more tender entheseal point) were recruited. Primary outcome measure was rate of major cDAPSA response at week 24 and secondary outcome measures were ACR 20 response, change in PASI score, Maastricht enthesitis score, Leeds dactylitis index, and health assessment questionnaire-disability index (HAQ-DI) and number of adverse events at week 24 between methotrexate and apremilast groups. A total of 31 patients were recruited (15 in the apremilast arm and 16 in the methotrexate arm) amongst whom 26 patients completed 24 weeks follow up (13 patients in the apremilast arm and 13 patients in the methotrexate arm). Median cDAPSA score at baseline was 23 (9) in the apremilast group and 20 (21) in the methotrexate group. No difference in major cDAPSA response at week 24 was observed between apremilast and methotrexate arm (20% vs. 37.5%; p = 0.433). In the secondary outcome measures, there was no significant differences between both the groups. Both the drugs were safe without any serious adverse events. There was no significant difference between methotrexate and apremilast in terms of efficacy as measured by cDAPSA and ACR20 responses..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Rheumatology international - 43(2023), 5 vom: 24. März, Seite 841-848 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Samanta, Joydeep [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Antirheumatic agents |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00296-023-05315-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR049940678 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049940678 | ||
| 003 | DE-627 | ||
| 005 | 20230406064733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230406s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-023-05315-4 |2 doi | |
| 035 | |a (DE-627)SPR049940678 | ||
| 035 | |a (SPR)s00296-023-05315-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Samanta, Joydeep |e verfasserin |0 (orcid)0000-0002-1549-802X |4 aut | |
| 245 | 1 | 0 | |a Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract To compare the efficacy of methotrexate and apremilast in psoriatic arthritis (PsA). This Single blinded (physician), parallel group, randomized controlled trial was conducted at a single centre between October 2019 and December 2020. Adult PsA patients (age > 18 years), fulfilling CASPAR criteria, not on methotrexate/apremilast in last 3 months and never receiving bDMARDs or, JAK inhibitors, having active articular disease (one or more swollen joint or, having one or more tender entheseal point) were recruited. Primary outcome measure was rate of major cDAPSA response at week 24 and secondary outcome measures were ACR 20 response, change in PASI score, Maastricht enthesitis score, Leeds dactylitis index, and health assessment questionnaire-disability index (HAQ-DI) and number of adverse events at week 24 between methotrexate and apremilast groups. A total of 31 patients were recruited (15 in the apremilast arm and 16 in the methotrexate arm) amongst whom 26 patients completed 24 weeks follow up (13 patients in the apremilast arm and 13 patients in the methotrexate arm). Median cDAPSA score at baseline was 23 (9) in the apremilast group and 20 (21) in the methotrexate group. No difference in major cDAPSA response at week 24 was observed between apremilast and methotrexate arm (20% vs. 37.5%; p = 0.433). In the secondary outcome measures, there was no significant differences between both the groups. Both the drugs were safe without any serious adverse events. There was no significant difference between methotrexate and apremilast in terms of efficacy as measured by cDAPSA and ACR20 responses. | ||
| 650 | 4 | |a Psoriasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Psoriatic arthritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Spondyloarthritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antirheumatic agents |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Methotrexate |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Apremilast |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Naidu, GSRSNK |0 (orcid)0000-0002-9727-044X |4 aut | |
| 700 | 1 | |a Chattopadhyay, Arghya |0 (orcid)0000-0003-3917-1977 |4 aut | |
| 700 | 1 | |a Basnet, Amal |0 (orcid)0000-0001-5082-4954 |4 aut | |
| 700 | 1 | |a Narang, Tarun |0 (orcid)0000-0002-0464-2989 |4 aut | |
| 700 | 1 | |a Dhir, Varun |0 (orcid)0000-0002-3626-0694 |4 aut | |
| 700 | 1 | |a Dogra, Sunil |0 (orcid)0000-0001-9912-0085 |4 aut | |
| 700 | 1 | |a Jain, Sanjay |0 (orcid)0000-0002-0141-7655 |4 aut | |
| 700 | 1 | |a Sharma, Aman |0 (orcid)0000-0003-0813-1243 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Berlin : Springer, 1981 |g 43(2023), 5 vom: 24. März, Seite 841-848 |w (DE-627)SPR00382473X |w (DE-600)1464208-6 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2023 |g number:5 |g day:24 |g month:03 |g pages:841-848 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00296-023-05315-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2023 |e 5 |b 24 |c 03 |h 841-848 | ||